KYTX
NASDAQ HealthcareKyverna Therapeutics, Inc. - Common Stock
Biotechnology
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
๐ Market Data
| Price | $8.87 |
|---|---|
| Volume | 519,035 |
| Market Cap | 536.90M |
| Beta | 2.640 |
| RSI (14-Day) | 45.3 |
| 200-Day MA | $7.03 |
| 50-Day MA | $8.73 |
| 52-Week High | $13.67 |
| 52-Week Low | $1.92 |
| Forward P/E | -3.11 |
| Price / Book | 2.31 |
๐ฏ Investment Strategy Scores
KYTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (98/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find KYTX in your text
Paste any article, transcript, or post โ the tool will extract KYTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.